Cardiology

Inhibiting ApoC-III reduces triglyceride levels in mice

Some individuals remain at high risk for developing cardiovascular disease even after preventative treatment with cholesterol-lowering medications. This persistent risk has been linked to triglyceride levels, which can remain ...

Medications

Evolocumab: No hint of added benefit

Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. ...

page 35 from 38